soul trial oral semaglutide cardiovascular outcomes 2025 results European Abstract 4367751: Cardiovascular Outcomes of

Another industry group that represents larger compounding pharmacies sued the FDA in October over its decision to take tirzepatide off its list of drugs experiencing shortages

This is reporting-rate evidence, not incidence, and it is vulnerable to reporting bias and missing denominators

Other studies concluded that in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss. In another study, stimulation of GLP-1s by the agonist leads to body weight loss independent of reduction in food intake

Central administration of GLP-1 in rats and mice stimulates the HPA axis and increases secretion of corticosterone, and this is accompanied by increased cFOS immunoreactivity in CRH-positive neurons in the PVN [668,698,814]

Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C

All content in this article is sourced from the webinar Starting Strong: Guide to Starting GLP-1 Medications hosted by Dr